Genetic Technologies Limited (GENE)
-NasdaqCM 2.58 
0.11(4.12%) 4:00PM EDT
| Prev Close: | 2.69 |
|---|
| Open: | 2.74 |
|---|
| Bid: | N/A |
|---|
| Ask: | 3.94 x 400 |
|---|
| 1y Target Est: | 1.50 |
|---|
| Beta: | 0.49 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.40 - 2.74 |
|---|
| 52wk Range: | 2.00 - 4.79 |
|---|
| Volume: | 202,767 |
|---|
| Avg Vol (3m): | 119,691 |
|---|
| Market Cap: | 40.50M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Genetic Technologies provides U.S. gene patenting update; Genetic Technologies' non-coding patents not affected, BRCA testing not affected, BREVAGen testing not affected, immunaid technology not affectedBriefing.com(Mon, Jun 17)
- Genetic Technologies Provides U.S. Gene Patenting UpdateMarketwired(Sun, Jun 16)
- Genetic Technologies Executes Agreement With MultiPlan, Inc., a Nationwide Provider NetworkMarketwired(Mon, May 20)
- 3 Healthcare Stock Stories For Weekend Investment Wellnessat Wall St. Cheat Sheet(Sat, May 4)
- Nike’s Upcoming Quarter, Staples Brings 3D Printers to the Masses, and 3 More Hot Stocksat Wall St. Cheat Sheet(Fri, May 3)
- Genetic Technologies Executes Agreement With Nationwide Provider NetworkMarketwired(Fri, May 3)
- Genetic Technologies upgraded by Ladenburg ThalmannBriefing.com(Fri, May 3)
- Genetic Technologies Announces Financial Results for Quarter Ended March 31, 2013Marketwired(Tue, Apr 30)
- STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCEGlobeNewswire(Mon, Apr 15)
- Genetic Technologies Provides U.S. Patent Re-Examination UpdateMarketwired(Fri, Mar 15)
- 5 Stocks Ready to Break Outat TheStreet(Fri, Feb 22)
- Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2012Marketwired(Fri, Feb 22)
- Genetic Technologies Appoints Chief Executive Officer and Non-Executive DirectorMarketwired(Mon, Dec 10)
- Genetic Technologies Provides Update on Board and Management ChangesMarketwired(Thu, Nov 29)
- Genetic Technologies lower following resignation of CEOtheflyonthewall.com(Tue, Nov 27)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.64 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.45 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Genetic Technologies Limited provides genetic testing services. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and ...
View More